Identification of Prognostic Signature and Gliclazide as Candidate Drugs in Lung Adenocarcinoma

BACKGROUND: Lung adenocarcinoma (LUAD) is the most common pathological type of lung cancer, with high incidence and mortality. To improve the curative effect and prolong the survival of patients, it is necessary to find new biomarkers to accurately predict the prognosis of patients and explore new s...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Front Oncol
Autors principals: Cheng, Yang, Hou, Kezuo, Wang, Yizhe, Chen, Yang, Zheng, Xueying, Qi, Jianfei, Yang, Bowen, Tang, Shiying, Han, Xu, Shi, Dongyao, Wang, Ximing, Liu, Yunpeng, Hu, Xuejun, Che, Xiaofang
Format: Artigo
Idioma:Inglês
Publicat: Frontiers Media S.A. 2021
Matèries:
Oncology
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8264429/
https://ncbi.nlm.nih.gov/pubmed/34249701
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2021.665276
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars